TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05354700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and etoposide
Description: chemotherapeutics
Study: NCT05229315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy
Study: NCT01244607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0801
Description: single i.v. administration
Study: NCT05350982

Intervention type: DEVICE
Intervention: SalivaBio +/- SaliPac
Description: Sterile collection swab (SalivaBio), Modified dummy (SaliPac)

Intervention type: DEVICE
Intervention: SalivaBio +/- SaliPac
Description: Sterile collection swab (SalivaBio), Modified dummy (SaliPac)
Study: NCT04031066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velmanase Alfa
Description: infusion i.v. treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion i.v. treatment
Study: NCT05578417

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study: NCT05834257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline for fluid resuscitation
Description: Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Normal Saline infusion (as clinically prescribed).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PlasmaLyte for fluid resuscitation
Description: Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ringer's Lacatate for fluid resusciation
Description: Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
Study: NCT06304545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab IV 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Capecitabine PO oxaliplatin IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 50Gy /45Gy /25 fractions
Study: NCT05991245

Intervention type: OTHER
Intervention: Collecting datas
Description: Blood, Tissue and Urine samples
Study: NCT05205668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-652
Description: IL-22 fusion protein administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-652
Description: IL-22 fusion protein administered intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously
Study: NCT05269017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Devarol S amp containing 200,000 units per 2 ml giving a concentration of 5,000 units per drops for four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64 µg per puff in a dose of 1 puff for each nostril twice daily for four weeks
Study: NCT06190782

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor+/- chemotherapy combined with local therapy
Description: 1. PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~   First line:~   i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)~2. Local therapy i. Radiotherapy GTV=all suspected lesions. SBRT: for lung, liver, adrenal gland, celiac lymphnode metatstases 48Gy/6fx; for spine metastatic disease 30Gy/10Fx; for brain metastases 24Gy/30fx; IMRT: for bone metastatic disease 30Gy/10fx; for esophageal lesion or lesion unsuitable of SBRT 50.4Gy/28fx; ii. Surgery iii. Radiofrequency/microwave ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy alone
Description: 1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)
Study: NCT05115331

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental Radiation Dose
Description: 16 Gy in 2 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiation Dose
Description: 8 Gy in a single fraction
Study: NCT06006351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: manual therapy stretching exercises strengthening exercises electrotherapy applications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: manual therapy stretching exercises strengthening exercises electrotherapy applications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypervolt Device
Description: The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
Study: NCT04821440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water displacement volumetry
Description: The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water displacement volumetry
Description: The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three dimension volumetry
Description: The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three dimension volumetry
Description: The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
Study: NCT06085742

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 60mg/m2 PO once a day (21 continuous days)

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: 10mg/m2 PO BID on days 1, 8, and 15

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 825mg/m2 PO BID on days 1-14
Study: NCT06118671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized lifestyle intervention by AI
Description: The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
Study: NCT03779685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Sevoflurane and morphine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Paravertebral block
Study: NCT05725707

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friendship Group
Description: Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friendship Group
Description: Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
Study: NCT06427330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: 1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2
Study: NCT05837598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Cancer and Mental Health Tumor Board
Description: The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.
Study: NCT06097611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid administration
Description: Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid administration
Description: Tranexamic Acid administration to compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury
Study: NCT05540977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5mg QN

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT04087083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technological intervention arm
Description: Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Each session will include 50 minutes of traditional physical rehabilitation therapy
Study: NCT03908112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Concussion Care (SC)
Description: temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SC plus Simple Convergence Exercises (SC+)
Description: In addition to standard community care in this intervention the participants must perform convergence therapy every day at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)
Description: In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
Study: NCT06481423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBT-I
Description: A digital cognitive behavioral intervention course that addresses multiple aspects such as basic sleep knowledge, sleep hygiene, sleep behaviors, improving negative cognition, and improving emotions. The intervention is delivered through video, audio, and text formats.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxing music
Description: Participants can freely listen relaxing music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxing music
Description: Participants can freely listen relaxing music
Study: NCT06416137

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).
Study: NCT05860322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT06143215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 weeks revision
Description: In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 weeks revision
Description: In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 weeks revision
Description: In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 2-4-6 weeks revision times could change diabetic foot reulceration rate.
Study: NCT04724317

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Steroid Group
Description: Ultrasound guided shoulder intra-articular steroid injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone Group
Description: Ultrasound guided shoulder intra-articular Ozone injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF Group
Description: Ultrasound guided shoulder intra-articular pulsed radiofrequency application
Study: NCT06081309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-based personalized TMS
Description: Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
Study: NCT05814523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone will be administered as IV solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IV solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
Study: NCT06558318

Intervention type: OTHER
Intervention: Assessment of temporomandibular dysfunction
Description: TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.

Intervention type: OTHER
Intervention: Assessment of temporomandibular dysfunction
Description: TMJ dysfunction will be measured using the Fonseca Amnestic Index. The Fonseca Amnestic Index is used to assess the severity of temporomandibular joint (TMJ) dysfunction. The index consists of 10 questions, with each question scored as 0, 5, or 10 points, depending on the severity of symptoms. The maximum total score is 100, where a higher score indicates a more severe level of TMJ dysfunction. Therefore, patients with higher scores on the Fonseca Amnestic Index are considered to have more significant TMJ issues. Based on Fonseca scores, two groups will be formed: those with scores over 20 will be labeled 'with TMJ dysfunction,' and the others 'without TMJ dysfunction.
Study: NCT05528120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 Capsules
Description: Oral administration after fasting/high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 Capsules
Description: Oral administration after high-fat/fasting meal
Study: NCT05974371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional context similarity
Description: On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
Study: NCT05828433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epley-Canalith Repositioning
Description: Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Therapy
Description: Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks.